What happened with INSM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Insmed’s main product is ARIKAYCE, an inhaled antibiotic for specified groups of patients with lung disease caused by Mycobacterium avium complex, or MAC. It supplies most of the company’s product revenue and is sold in the United States, Europe and Japan. Its other commercial medicine, BRINSUPRI, is a once-daily tablet for bronchiectasis not caused by cystic fibrosis, a condition involving damaged, widened airways. BRINSUPRI is sold in the United States and is also approved in the European Union for a restricted patient population.
In the United States, specialty pharmacies and a specialty distributor buy Insmed’s medicines, while insurance coverage helps patients pay for treatment. Most product sales come from the United States, and a small group of customers accounts for most gross product revenue. Medicare reimbursement supports a significant portion of US revenue from both drugs, making coverage decisions, access restrictions and negotiated prices central to the business.
Insmed relies on outside manufacturers for its commercial medicines. ARIKAYCE delivers amikacin directly to the lungs through the Lamira nebulizer, which PARI alone supplies; Insmed cannot sell ARIKAYCE without that delivery system. ARIKAYCE’s US approval is accelerated rather than full approval, and retaining it depends on confirming clinical benefit through required follow-up studies. Both medicines can be marketed only within their approved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Insmed’s current revenue depends on adoption of ARIKAYCE and BRINSUPRI; privately held PARI is also essential, supplying the Lamira nebulizer that delivers ARIKAYCE.
United Therapeutics already sells inhaled treprostinil to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), putting it in the markets Insmed’s late-stage TPIP aims to enter. Sales of its Tyvaso DPI and nebulized Tyvaso are worth watching for demand in those patient groups.
Liquidia Corporation earns revenue from YUTREPIA inhalation powder for PAH and PH-ILD, directly competing in the market Insmed targets with once-daily TPIP. Watch whether TPIP trials show that less frequent dosing can deliver efficacy and safety similar to YUTREPIA—that could make TPIP a more attractive choice and win market share quickly.
Insmed depends on AstraZeneca’s licensed patents for BRINSUPRI, its bronchiectasis treatment, and must meet development obligations while potentially paying milestones and royalties. AstraZeneca can terminate the license if Insmed fails to use commercially reasonable development and commercialization efforts, making compliance important to keeping BRINSUPRI’s licensed rights.
Merck’s marketed Winrevair competes for PAH treatment use in the market Insmed’s TPIP aims to enter. Winrevair’s sales and use among PAH patients are more relevant to that competitive position than Merck’s company-wide sales of medicines, vaccines and animal health products.
Insmed, Inc. earningsThis company
Insmed’s report will show whether BRINSUPRI’s US launch keeps adding sales and ARIKAYCE keeps growing, sustaining the company’s product revenue.
Read sales of the two products together: whether BRINSUPRI continues to add sales after its US launch, and whether ARIKAYCE keeps growing while Japan remains the largest part of its international revenue. Growth in both would show that each product is contributing; weak BRINSUPRI growth or slower ARIKAYCE sales would leave revenue growth more reliant on the new launch and show less support from the established product.
Merck & Co., Inc. earningsMRK
If Merck reports Winrevair sales and use, its results will show PAH treatment demand and the competition facing Insmed’s planned TPIP.
If disclosed, look at Winrevair sales and use among PAH patients. Rising use would validate treatment demand but show TPIP would face a stronger competitor; weak use would mean demand is less evident, not that TPIP has an easier path into the market.
AstraZeneca PLC earningsAZN
AstraZeneca’s report may offer clues about its BRINSUPRI license relationship with Insmed, which supports Insmed’s rights to the drug; company-wide sales alone cannot show whether the partnership is secure.
Look for disclosure about BRINSUPRI development or the license relationship. Continued progress would be consistent with Insmed maintaining its licensed rights; signs of reduced commitment would make the relationship worth watching. AstraZeneca’s overall results cannot establish whether Insmed has met its obligations or whether the license will continue.
Liquidia Corporation earningsLQDA
Liquidia Corporation’s report will show how patients with PAH and PH-ILD are responding to inhaled treprostinil, the market Insmed’s planned TPIP would enter.
Look at YUTREPIA sales and use in PAH and PH-ILD. Growth would show that patients and prescribers are adopting inhaled treprostinil, establishing demand for TPIP but also a competitor; weak sales would suggest the market itself may be harder to build, not that TPIP has an easier path.
United Therapeutics Corp earningsUTHR
United Therapeutics’ report will show demand for inhaled treprostinil in PAH and PH-ILD, the markets Insmed’s planned TPIP would enter against Tyvaso.
Look at sales of Tyvaso DPI and nebulized Tyvaso. Growth would show established demand for inhaled treprostinil in PAH and PH-ILD, supporting a market for TPIP but also signaling a strong incumbent; flat or falling sales would point to a weaker demand base for TPIP to enter.
